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A B S T R A C T
Background
Severe pre-eclampsia can cause significant mortality and morbidity for both mother and child, particularly when it occurs remote from
term, between 24 and 34 weeks’ gestation. The only known cure for this disease is delivery. Some obstetricians advocate early delivery
to ensure that the development of serious maternal complications, such as eclampsia (fits) and kidney failure are prevented. Others
prefer a more expectant approach delaying delivery in an attempt to reduce the mortality and morbidity for the child associated with
being born too early.
Objectives
The objective of the review was to compare the effects of a policy of interventionist care and early delivery with a policy of expectant
care and delayed delivery for women with early onset severe pre-eclampsia.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (28 February 2013).
Selection criteria
Randomised trials comparing the two intervention strategies for women with early onset severe pre-eclampsia.
Data collection and analysis
Two review authors independently assessed trials for inclusion, extracted data and assessed risk of bias. Data were checked for accuracy.
Main results
Four trials, with a total of 425 women are included in this review. Trials were at low risk of bias for methods of randomisation and
allocation concealment; high risk for blinding; unclear risk for incomplete outcome data and other bias; and low risk for selective
reporting. There are insufficient data for reliable conclusions about the comparative effects on most outcomes for the mother. For the
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baby, there is insufficient evidence for reliable conclusions about the effects on stillbirth or death after delivery (risk ratio (RR) 1.08,
95% confidence interval (CI) 0.69 to 1.71; four studies; 425 women). Babies whose mothers had been allocated to the interventionist
group hadmore intraventricular haemorrhage (RR 1.82, 95%CI 1.06 to 3.14; one study; 262 women), more hyalinemembrane disease
(RR 2.30, 95% CI 1.39 to 3.81; two studies; 133 women), require more ventilation (RR 1.50, 95% CI 1.11 to 2.02; two studies; 300
women) and were more likely to have a lower gestation at birth in days (average mean difference (MD) -9.91, 95% CI -16.37 to -3.45;
four studies; 425 women), more likely to be admitted to neonatal intensive care (RR 1.35, 95% CI 1.16 to 1.58) and have a longer
stay in the neonatal intensive care unit (average MD 11.14 days, 95% CI 1.57 to 20.72 days; two studies; 125 women) than those
allocated an expectant policy. Nevertheless, babies allocated to the interventionist policy were less likely to be small-for-gestational age
(RR 0.30, 95% CI 0.14 to 0.65; two studies; 125 women). Women who had been allocated to the interventionist group were more
likely to have a caesarean section (RR 1.09, 95% CI 1.01 to 1.18; four studies; 425 women) than those allocated an expectant policy.
There were no statistically significant differences between the two strategies for any other outcomes.
Authors’ conclusions
This review suggests that an expectant approach to the management of women with severe early onset pre-eclampsia may be associated
with decreased morbidity for the baby. However, this evidence is based on data from only four trials. Further large trials are needed to
confirm or refute these findings and establish if this approach is safe for the mother.
P L A I N L A N G U A G E S U M M A R Y
Interventionist versus expectant care for severe pre-eclampsia before term
Women who develop pre-eclampsia (high blood pressure and protein in the urine) before 34 weeks of pregnancy (early onset) are at risk
of severe complications, and even death. These involve the woman’s liver, kidneys, clotting system and cause neurological disturbances
such as headache, visual disturbances, and exaggerated tendon reflexes. If the placenta is involved, this can cause growth restriction or
reduced amniotic fluid, placing the baby at risk. The only known cure for pre-eclampsia is delivery of the baby. Being born too early
can in itself have problems for the baby, even with the administration of corticosteroids 24 to 48 hours beforehand to help mature the
lungs. Some hospitals follow a policy of early delivery within 24 to 48 hours, interventionist management, whilst others prefer to delay
delivery until it is no longer possible to safely stabilise the woman’s condition, expectant management.
This review included four trials that randomly assigned women to a policy of interventionist management or expectant management
when presenting with severe pre-eclampsia before 34 weeks of pregnancy. A total of 425 women were included in these four trials.
Babies born to women allocated to an interventionist approach were more likely to experience adverse effects such as intraventricular
haemorrhage and neonatal respiratory distress syndrome. They were also more likely to require admission to the neonatal intensive care
unit and ventilation, have a longer stay in the neonatal unit and weigh less at birth than those babies born to women allocated to an
expectant management approach. Women in the interventionist group were also more likely to require caesarean section for delivery.
Delaying delivery may therefore be more beneficial for the baby. There are insufficient data, however, for reliable conclusions about the
comparative effects on most outcomes for the mother and hence the maternal safety of an expectant approach.
This evidence is based on data from only four small trials. Further large trials with long-term follow-up of the children are needed to
confirm or refute whether expectant care is better than early delivery for women who suffer from severe pre-eclampsia before 34 weeks
of pregnancy.
B A C K G R O U N D
Pre-eclampsia is a multisystem disorder that is usually associated
with raised blood pressure and proteinuria, but can also involve the
woman’s liver, kidneys, clotting system, or brain. If the placenta is
involved this may lead to growth restriction or premature birth.
Pre-eclampsia is a relatively common complication of pregnancy,
and can occur at any time during the second half of pregnancy or
in the first few weeks after delivery. Prediction models for adverse
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maternal outcome have been developed and validated in recent
times (von Dadelszen 2011), but there is still a paucity of data to
guide the clinician on the timing of delivery to ensure safety of
both the mother and the baby in the long term. Pre-eclampsia is
described in more detail in the generic protocol on interventions
for treatment of pre-eclampsia and its consequences (Duley 2009).
Description of the condition
Hypertension in pregnancy is defined as a systolic blood pressure
of 140 mmHg or more, and/or a diastolic pressure of 90 mmHg
or more. To be diagnosed with pre-eclampsia the hypertension has
to arise de novo after 20 weeks of pregnancy in combination with
proteinuria defined as greater than 300 mg of total protein in a
24-hour urine collection (Davey 1988). Recently, proteinuria has
been assessed using a spot urinemeasuring the protein to creatinine
ratio. A protein: creatinine ratio of 30 mg/mmol correlates with
a 24-hour protein excretion of greater than 300 mg in 24 hours
(Morris 2012). This method of estimating the amount of protein
being excreted has several advantages over the 24-hour urine col-
lection and has been endorsed in a Royal College of Obstetricians
and Gynaecologists (RCOG) Pre-eclampsia study group consen-
sus statement (RCOG 2003). However, pre-eclampsia is a multi-
system disorder and the diagnosis of hypertension and proteinuria
is considered to be too restrictive for clinical practice. Clinicians
are all too aware that the disease can present in several ways and it
is necessary to be vigilant when assessing women with symptoms
and signs that are strongly associated with the disease. This has
led to a widening of the definition for clinical purposes, to in-
clude the following: de novo hypertension after 20weeks’ gestation
and new onset of one of the following: a) proteinuria as defined
above; b) renal insufficiency (creatinine > 0.09 mmol/L, or olig-
uria; c) liver disease (raised transaminases and/or severe right upper
quadrant or epigastric pain); d) neurological problems, convul-
sions (eclampsia), hyper-reflexia with clonus (involuntary muscu-
lar contractions), severe headaches, persistent visual disturbances
(scotoma); e) haematological disturbances: thrombocytopenia (re-
duced numbers of platelets), disseminated intravascular coagula-
tion, haemolysis; or f ) fetal growth restriction (Brown 2001).
There is no widely accepted definition of severe pre-eclampsia
(Duley 2009). Nevertheless, the features described above in com-
bination with the early onset of the disease between 24 and 34
weeks’ gestation, would be considered by most clinicians to repre-
sent severe pre-eclampsia. We therefore did not further define nor
categorise “severity”.
Description of the intervention
Within clinical practice, some units advocate early delivery, which
has been referred to as ’aggressive management’ (Sibai 1984), but
in this review the term ’interventionist’ is preferred. This means
delivery by either induction of labour or caesarean section after
corticosteroids have been given to improve fetal lung maturation,
which in practice is after 24 to 48 hours (Crowley 1996). Others
prefer to give corticosteroids, stabilise the woman’s condition and
then, if possible, aim to delay delivery. This is usually known as
’expectant management’ (Derham 1989). The greatest dilemma
in when to deliver is balancing the risks to mother and baby when
the pregnancy is somewhere between 24 to 34 weeks. Early deliv-
ery resulting in a very premature baby could lead to more neonatal
complications such as respiratory distress syndrome (difficulty in
breathing and oxygenation), intraventricular haemorrhage (bleed-
ing into the cavities of the brain) and necrotising enterocolitis
(bleeding into the wall of the bowel due to a lack of oxygen). Con-
versely, delaying delivery in an attempt to allow fetal maturation
could place the mother in jeopardy and at risk of multisystem
organ failure as outlined above. It also prolongs the time that a
fetus is in a potentially hostile in utero environment. This in turn
will continue to adversely affect the growth of the fetus and may
result in an intrauterine death, from severe hypoxia or an acute
event such as an abruption. Although the precise cut offs for ges-
tational age will vary with different settings, before 24 weeks the
child has little chance of survival. After 34 weeks the prognosis
improves with nearly 100 per cent survival. Between 24 and 34
weeks mortality decreases with increasing gestational age, but es-
pecially below 28 weeks there is also considerable risk of survival
with severe disability. A structured review of observational stud-
ies found that expectant care for severe pre-eclampsia was associ-
ated with a prolongation of the pregnancy by between one and
two weeks with better outcomes for babies and low risks for the
mother. There were fewer neonatal deaths and complications of
prematurity (Magee 2009).
Why it is important to do this review
This difficult clinical dilemma occurs relatively frequently in large
units, and currently decisions are based mainly upon personal
experience rather than good evidence. There is a great need for
reliable data to help inform this decision-making.
Other aspects of care forwomenwith severe pre-eclampsia are dealt
with in other reviews. These include drugs for lowering very high
blood pressure (Duley 2006), prophylactic anticonvulsants (Duley
2010) and plasma volume expansion (Duley 1999b). Prevention
of pre-eclampsia is covered by reviews of calcium supplementation
(Hofmeyr 2010), antiplatelets (Duley 2007), salt intake (Duley
1999a; Duley 2005) and magnesium supplementation (Makrides
2001).
O B J E C T I V E S
To evaluate the comparative benefits and risks of a policy of early
delivery by induction of labour or by caesarean section after suf-
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ficient time has elapsed to administer corticosteroids, and allow
them to take effect; with a policy of delaying delivery (expectant
care) for women with severe pre-eclampsia between 24 and 34
weeks.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All adequately randomised trials comparing interventionist (ag-
gressive) with expectant care (delayed delivery) for women with
severe early onset pre-eclampsia. Quasi-random designs, such as
alternate numbers or allocation by the day of the week, were ex-
cluded.
Types of participants
Women with severe pre-eclampsia before or equal to 34 weeks’
gestation. Severe pre-eclampsia was defined as high blood pressure,
> 140/90 mmHg on two consecutive occasions four or more hours
apart and proteinuria greater than 300 mg/24 hours. Alternatively
as:
• severe hypertension (blood pressure at least 160 mmHg
systolic, or 110 mmHg diastolic) alone;
or hypertension as defined above plus one or more of the following
criteria:
• severe proteinuria (usually at least 3 g (range 2 g to 5 g)
protein in 24 hours, or 3+ on dipstick);
• reduced urinary volume (less than 500 mL in 24 hours),
upper abdominal pain, pulmonary oedema;
• neurological disturbances (such as headache, visual
disturbances, and exaggerated tendon reflexes);
• impaired liver function tests, high serum creatinine, low
platelets;
• suspected intrauterine growth restriction or reduced liquor
volume.
This latter set of criteria reflect the natural history of the disease
and clinical practice when diagnosing severe pre-eclampsia.
Types of interventions
Any comparison of a policy of early elective delivery by induction
of labour or by caesarean section (interventionist management)
with a policy of delayed delivery (expectant management). If cor-
ticosteroids were used within the trial, they should have been used
for both types of care. As the beneficial effects of a course of corti-
costeroids are so important, any study where corticosteroids were
only administered to one group but not the other was excluded.
Types of outcome measures
Primary outcomes
For the woman
• Death
• Eclampsia (fitting)
• Stroke (brain damage)
• HELLP (haemolysis, elevated liver enzymes and low
platelets) syndrome
• Pulmonary oedema (fluid in the lungs)
For the baby
• Stillbirth
• Neonatal death
• Intraventricular haemorrhage (bleeding in the brain) and/or
hypoxic ischaemic encephalopathy
Secondary outcomes
For the woman
• Renal failure (kidney failure)
• Liver failure
• Cardiac arrest
• The need for invasive monitoring, such as central venous
catheterisation (intravenous lines into the great veins around the
heart)
• Caesarean section
• Placental abruption
For the baby
• Low Apgar score at five minutes
• Neonatal seizures
• Hyaline membrane disease (stiff lungs)
• Pneumothorax (air leaks from the lungs)
• Necrotising enterocolitis (bleeding into the bowel wall)
• Ventilation (any ventilation, duration of ventilation)
• Measures of long-term growth and development, such as
important impairment and cerebral palsy
• Small-for-gestational age
• Gestation at birth
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Use of health service resources
• Need for intensive care for the woman
• Need for high-dependency care or observation, or both, for
the woman
• Length of stay in neonatal intensive care
• Admission to neonatal intensive care unit
• Surfactant for the baby
• Ventilation for the baby
Search methods for identification of studies
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s
Trials Register by contacting the Trials Search Co-ordinator (28
February 2013).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. weekly searches of Embase;
4. handsearches of 30 journals and the proceedings of major
conferences;
5. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE and
Embase, the list of handsearched journals and conference pro-
ceedings, and the list of journals reviewed via the current aware-
ness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
For details of additional searching carried out in the previous ver-
sion of the review, please see Appendix 1.
We did not apply any language restrictions.
Data collection and analysis
For the methods used when assessing the trials identified in the
previous version of this review, see Appendix 2.
For this update we used the following methods when assessing the
reports identified by the updated search. The two already included
studies (Odendaal 1990; Sibai 1994) were also re-assessed using
the following methods for ’Risk of bias’ assessment.
Selection of studies
Two review authors (D Churchill (DC); L Jones (LJ)) indepen-
dently assessed for inclusion all the potential studies identified as a
result of the search strategy.We resolved any disagreement through
discussion or, if required, we consulted a third author.
Data extraction and management
We designed a form to extract data. For eligible studies, two re-
view authors (DC; LJ) independently extracted the data using the
agreed form. We resolved discrepancies through discussion or, if
required, we consulted a third author. We entered data into Re-
view Manager software (RevMan 2012) and checked for accuracy.
When information regarding any of the above was unclear, we
contacted authors of the original reports to provide further details.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). Disagreement
was resolved by discussion or by involving a third author.
(1) Sequence generation (checking for possible selection
bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
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(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if theywere blinded, or if we judged that the
lack of blinding would be unlikely to affect results. We planned
to assess blinding separately for different outcomes or classes of
outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We planned to assess blinding separately for
different outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We stated whether attrition and ex-
clusions were reported and the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or could be supplied
by the trial authors, we planned to re-include missing data in the
analyses which we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting bias
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not prespecified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other sources of bias (checking for bias due to problems
not covered by (1) to (5) above)
We described for each included study any important concerns we
had about other possible sources of bias. We assessed whether each
study was free of other problems that could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Cochrane Hand-
book (Higgins 2011). With reference to (1) to (6) above, we as-
sessed the likely magnitude and direction of the bias and whether
we considered it likely to impact on the findings. We planned to
explore the impact of the level of bias through undertaking sensi-
tivity analyses - see Sensitivity analysis.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratios
with 95% confidence intervals.
Continuous data
For continuous data, we used the mean difference if outcomes
were measured in the same way between trials. We planned to use
the standardised mean difference to combine trials that measured
the same outcome, but used different methods, if required.
Unit of analysis issues
Cluster-randomised trials
If we identify cluster-randomised trials in future updates, we will
include them in the analyses along with individually-randomised
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trials.Wewill adjust their sample sizes using themethods described
in the Cochrane Handbook using an estimate of the intracluster
correlation co-efficient (ICC) derived from the trial (if possible),
from a similar trial or from a study of a similar population. If we
use ICCs from other sources, we will report this and conduct sen-
sitivity analyses to investigate the effect of variation in the ICC. If
we identify both cluster-randomised trials and individually-ran-
domised trials, we plan to synthesise the relevant information.
We will consider it reasonable to combine the results from both
if there is little heterogeneity between the study designs and the
interaction between the effect of intervention and the choice of
randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Cross-over trials
Cross-over trials are not a valid study design for this review.
Dealing with missing data
For included studies, we noted levels of attrition. We explored the
impact of including studies with high levels of missing data in the
overall assessment of treatment effect by using sensitivity analysis.
For all outcomes, we carried out analyses, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all partic-
ipants randomised to each group in the analyses, and all partici-
pants were analysed in the group to which they were allocated, re-
gardless of whether or not they received the allocated intervention.
The denominator for each outcome in each trial was the number
randomised minus any participants whose outcomes were known
to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the T2, I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if the T2 is greater than zero and either the I2 was greater
than 30% or there was a low P value (less than 0.10) in the Chi²
test for heterogeneity.
Assessment of reporting biases
In future updates, if there are 10 or more studies in the meta-
analysis we will investigate reporting biases (such as publication
bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2012).We used fixed-effect meta-analysis for com-
bining data where it was reasonable to assume that studies were
estimating the same underlying treatment effect: i.e. where trials
were examining the same intervention, and the trials’ populations
and methods were judged sufficiently similar. If there was clinical
heterogeneity sufficient to expect that the underlying treatment ef-
fects differed between trials, or if substantial statistical heterogene-
ity was detected, we used random-effects meta-analysis to produce
an overall summary if an averaged treatment effect across trials
was considered clinically meaningful. The random-effects sum-
mary was treated as the average of the range of possible treatment
effects and we discussed the clinical implications of treatment ef-
fects differing between trials. If the average treatment effect was
not clinically meaningful, we did not combine trials.
If we used random-effects analyses, the results were presented as
the average treatment effect with its 95% confidence interval, and
the estimates of T2 and I2.
Subgroup analysis and investigation of heterogeneity
In future updates, if we identify substantial heterogeneity, we will
investigate it using subgroup analyses and sensitivity analyses. We
will consider whether an overall summary is meaningful, and if it
is, use random-effects analysis to produce it.
We plan to carry out the following subgroup analyses based on:
1. gestation at trial entry: 24 to 28 weeks’ gestation; 29 to 34
weeks’ gestation; gestation mixed or unknown;
2. whether suspected intrauterine growth restriction at trial
entry: suspected intrauterine growth restriction; no suspected
intrauterine growth restriction; mixed or unknown.
The following primary outcomeswill be used in subgroup analysis.
For the woman
• Death
• Eclampsia (fitting)
• Stroke (brain damage)
• HELLP syndrome
• Pulmonary oedema
For the baby
• Stillbirth
• Neonatal death
• Intraventricular haemorrhage
We will assess differences between subgroups using interaction
tests available within (RevMan 2012).
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Sensitivity analysis
In future updates, if more studies are identified and included in
analyses, we plan to carry out sensitivity analyses to explore the
effect of trial quality assessed by concealment of allocation, high
attrition rates, or both, with poor quality studies being excluded
from the analyses in order to assess whether this makes any differ-
ence to the overall result.
R E S U L T S
Description of studies
Results of the search
A total of seven trials were identified and four trials met our inclu-
sion criteria (GRIT 2003; Mesbah 2003; Odendaal 1990; Sibai
1994) - see table of Characteristics of included studies.
Two trials were excluded (Gruppo di Studio1998; Langenveld
2011) - see table of Characteristics of excluded studies.
One trial is ongoing (Duvekot 2011) - see table ofOngoing studies.
Included studies
Four trials with a total of 425 women are included in this review.
Setting
One trial, was a UK basedmulti-centre trial involving 69 hospitals
in 13 European countries (GRIT 2003). The other three trials
were single-centre trials, based in Egypt (Mesbah 2003), South
Africa (Odendaal 1990), and the USA (Sibai 1994).
Participants
In one trial, (GRIT 2003), 548 pregnant women with fetal growth
restriction between 24 and 36 weeks’ gestation, an umbilical artery
Doppler waveform recorded and clinical uncertainty whether im-
mediate delivery was indicated were examined. A subset of women
from this trial (GRIT 2003) at less than or equal to 34 weeks’
gestation (n = 262), who had severe pre-eclampsia were included
in this review. Mesbah 2003 included 30 women with severe pre
eclampsia between 28 and 33 weeks’ gestation; Odendaal 1990
included 38 women with severe pre-eclampsia between 28 and 34
weeks’ gestation; and Sibai 1994 included 95 women with severe
pre-eclampsia at 28 to 32 weeks’ gestation.
Interventions
In all trials, women had a 24- to 48-hour period of stabilisation
during which they were given steroids to accelerate fetal lung ma-
turity and if necessary magnesium sulphate to prevent seizures and
antihypertensives to lower blood pressure. If they continued to
meet the eligibility criteria at the end of this period they were then
randomised. They were either randomised to the interventionist
group, which involved immediate delivery by caesarean section or
induction, or to the expectantmanagement group, whowereman-
aged with hospitalisation and intensive maternal and fetal moni-
toring. Earlier delivery in this expectant group was implemented if
either the maternal or fetal condition deteriorated, as determined
by prespecified criteria.
Outcomes
The main outcomes in all studies included maternal, perinatal
and neonatal morbidity and mortality outcomes. Only one trial
included long-term outcomes (GRIT 2003): measures of long-
term growth and development at two years.
For further details see Characteristics of included studies.
Excluded studies
Two trials were excluded as they did not meet the inclusion criteria
of the review (Gruppo di Studio1998; Langenveld 2011). In both
trials, the women did not have severe pre-eclampsia.
See table of Characteristics of excluded studies.
Risk of bias in included studies
The four trials were relatively small. Overall, two trials were judged
tohave a low risk of bias (GRIT 2003; Sibai 1994), onewas unclear
(Odendaal 1990) and one a high risk of bias (Mesbah 2003).
See Figure 1 and Figure 2 for summaries of ’Risk of bias’ assess-
ment.
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Figure 1. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
For one study, the method used for randomisation and conceal-
ment of allocation was not described (Odendaal 1990); in the
other, three trials both methods of randomisation and conceal-
ment were adequate (GRIT 2003; Mesbah 2003; Sibai 1994).
Blinding
Blinding of participants, personnel or outcome assessors was not
described in three of the trials (Mesbah 2003; Odendaal 1990;
Sibai 1994). Blinding of outcome assessment for long-term out-
comes such asGriffiths assessment was reported in one trial (GRIT
2003).
Incomplete outcome data
In one trial (Sibai 1994), all women appear to have been ac-
counted for in the results. In one trial individual patient data for
a subset of women with severe pre-eclampsia were provided by
the authors of the original trial and it is not possible to tell how
complete this data set is (GRIT 2003). In another trial, it is not
clear from results tables how many were included in the analyses
(Odendaal 1990). In one trial 41 women were recruited, but 11
(27%) were judged too compromised for expectant management
and were delivered by caesarean section and after randomisation,
five patients appear to be missing from the results table 2 (Mesbah
2003).
Selective reporting
All expected outcomes appear to have been reported upon in all
four trials (GRIT 2003; Mesbah 2003; Odendaal 1990; Sibai
1994).
Other potential sources of bias
In two studies, baseline characteristics were similar between groups
and no other sources of bias were apparent (Odendaal 1990;
Sibai 1994). In one study, other bias may have been introduced
as only a subset of the original randomised sample provided data
for analysis, but this was not clear (GRIT 2003). In one study,
the severe group were excluded from the study and no baseline
characteristics described for this group of patients (Mesbah 2003).
Effects of interventions
1. Interventionist care versus expectant (delayed
delivery) care for severe pre-eclampsia
Primary outcomes
Only one study (95 women) reported on primary outcomes of
relevance to the woman. In this study there were no reports of
eclampsia or pulmonary oedema in either group. There is insuffi-
cient evidence about the effects on HELLP (haemolysis, elevated
liver enzymes and low platelets) syndrome (one trial; 95 women;
risk ratio (RR) 0.53; 95% confidence interval (CI) 0.05 to 5.68),
Analysis 1.2. Death, stroke and pulmonary oedema were not re-
ported in any of the trials.
For the baby, there is insufficient evidence for any reliable conclu-
sions about the effects on stillbirth (four trials; 425 women; RR
0.20; 95% CI 0.03 to 1.16) or death after delivery (four trials;
425 women; RR 1.33; 95% CI 0.80 to 2.23), Analysis 1.5. Babies
whose mothers had been allocated to the interventionist group
had more intraventricular haemorrhage (one trial; 262 women;
RR 1.82, 95% CI 1.06 to 3.14), Analysis 1.6.
Secondary outcomes
Women allocated to the interventionist group were more likely to
have a caesarean section (four trials; 425 women; RR 1.09, 95%
CI 1.01 to 1.18), Analysis 1.18, than those allocated an expectant
policy. There were no statistically significant differences between
the two management strategies for renal failure (two trials; 133
women; RR 0.30, 95%CI 0.01 to 6.97), Analysis 1.7, or placental
abruption (two trials; 133 women; RR 0.80, 95% CI 0.26 to
2.40), Analysis 1.9. Liver failure, cardiac arrest and the need for
invasive monitoring for the woman were not reported in any of
the trials.
This review suggests that an interventionist policy of care may
be associated with increased morbidity for the baby. For example,
those babies whose mothers had been allocated to the interven-
tionist group had more hyaline membrane disease (two trials; 133
women; RR 2.30, 95%CI 1.39 to 3.81), Analysis 1.12, were more
likely to require ventilation (two trials; 300 women; RR 1.50, 95%
CI 1.11 to 2.02), Analysis 1.14, and were more likely to have a
lower gestation at birth (days) (four trials; 425 women; random-
effects analysis; average mean difference (MD) -9.91, 95% CI -
16.37 to -3.45; Heterogeneity: Tau² = 31.74; I² = 76%), Analysis
1.19. Also, babies whose mothers had been allocated to the inter-
ventionist group were at increased risk of developing necrotising
enterocolitis, (three trials; 395 women; RR 2.10, 95% CI 0.93
to 4.79), Analysis 1.13, although the results were not statistically
significant, the confidence interval only just overlaps the line of no
effect. This effect could be clarified bymore data in future updates.
Nevertheless, babies allocated to the interventionist policy were
less likely to be small-for-gestational age (two trials; 125 women;
RR 0.30, 95% CI 0.14 to 0.65), Analysis 1.18. There were no
statistically significant differences between the two management
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strategies for low Apgar score at five minutes, neonatal seizures,
and measures of long-term growth and development, see Analysis
1.10; Analysis 1.11; Analysis 1.15; Analysis 1.16; Analysis 1.17.
Babies whose mothers had been allocated to the interventionist
group were more likely to be admitted to neonatal intensive care
(two trials; 125 women; RR 1.35, 95% CI 1.16 to 1.58), Analysis
1.21, and have a longer stay in the neonatal intensive care unit (two
trials; 125 women; random-effects analysis; average MD 11.14
days, 95% CI 1.57 to 20.72 days; Heterogeneity: Tau² = 40.93; I²
= 85%), Analysis 1.20, than those allocated an expectant policy.
Other outcomes on use of health service resources were not re-
ported in any of the trials (need for intensive care for the woman;
need for high-dependency care or observation, or both, for the
woman; surfactant for the baby).
D I S C U S S I O N
Timing the delivery of a very premature infant in the presence
of severe pre-eclampsia is a difficult clinical decision. When the
mother’s life is in danger there is no doubt that delivery is the
only correct course of action. This situation is rare. More usually,
the risks of maternal morbidity or intrauterine fetal demise, if the
pregnancy is continued, have to be constantly balanced against the
hazards of prematurity to the fetus if delivered. Most obstetricians
would probably be cautious and expedite delivery in favour of the
outcome for the mother and being able to guarantee a live baby at
delivery. What is not clear is to what level this (if at all), adversely
affects the baby.
Only the GRIT study pre-specified fetal assessment parameters as
entry criteria into the study.The other studies used fetal assessment
to trigger delivery if there was evidence of significant compromise.
It is therefore not possible to compare the trials for the condition
of the fetuses on trial entry. However it is unlikely that there would
have been any clinical differences where this was not formally
assessed at trial entry. If there were signs of imminent fetal demise
then the women would not have been randomised into the trials.
But there is the potential for unseen bias and future trials must
include a formal assessment of fetal wellbeing on trial entry.
Currently there are insufficient data to justify any of our prespec-
ified subgroup analyses. These will be included in future updates
of this review, when larger trials become available.
It is not possible to draw firm conclusions from this review. How-
ever, the evidence is promising that short-term morbidity for the
baby may be reduced by a policy of expectant care. This is perhaps
surprising given that expectant management increases the length
of time a fetus is within the hostile environment, with the poten-
tial to adversely affect fetal growth. In fact this is often stated as a
reason for intervention. The results of this review suggest other-
wise. While the babies in the expectant management group were
smaller, their short-term outcomes were better. Before this policy
can be recommended in clinical practice, further evidence is re-
quired to demonstrate that there is truly a short-term benefit for
the baby and that it continues in the longer term. Reassurance is
also needed to demonstrate that there is no increase in mortality
for the child, or in morbidity for the mother.
Summary of main results
There is insufficient evidence for reliable conclusions about the
effects of either management approach on stillbirth or death af-
ter delivery. However, there is some evidence from this review to
suggest that a policy of delaying delivery reduces the morbidity
experienced in the neonatal period of life. Fewer babies had intra-
ventricular haemorrhages, hyaline membrane disease and reduced
levels of ventilation in those allocated to expectant management.
Babies in this group were also less likely to be admitted to the
neonatal intensive care unit and when admitted stayed there for
shorter periods of time. There were insufficient data to draw any
conclusions about the effect a policy of expectant care had on the
mothers health. None of the studies included had sufficient sam-
ple size to demonstrate differences in maternal outcome.
Overall completeness and applicability of
evidence
There is insufficient evidence from this review to recommend a
particular management policy for this area of obstetric care. The
numbers of participants in the trials is too small to be able to
demonstrate differences in most significant (primary) outcomes
and where differences are found there is a considerable level het-
erogeneity or the contribution is from only one trial. The same is
true for the analysis of the secondary outcome measures.
Quality of the evidence
Three of the trials included in the review were judged to be at un-
clear risk of both performance and detection bias. It is not possi-
ble to blind personnel and participants to interventions and most
outcomes are objective outcomes, and are unlikely to be affected
by blinding e.g. death, eclampsia. One study (Mesbah 2003), was
in addition judged to be at risk of attrition bias. The GRIT 2003
trial was not originally designed to examine severe pre-eclampsia.
It looked at interventionist versus expectant management for ba-
bies with growth restriction. A by-product of this study, was that
a subset of women also had severe pre-eclampsia and it is these
women who have been included in the review.
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Potential biases in the review process
J Thornton was the Principle Investigator for the GRIT 2003
trial. To remove the potential for bias, the GRIT trial data were
supplied directly to two other review authors (D Churchill, L
Jones) from the trial statistician. J Thornton had no dealings with
the acquisition, preparation or analysis of the GRIT trial data in
this review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
These data are insufficient to reach any firm conclusions about
the comparative effects of these alternative strategies for the care
of women with severe early onset pre-eclampsia. Nevertheless, the
apparent increase in some measures of neonatal morbidity asso-
ciated with interventionist care suggests that early delivery would
need to be justified by a realistic expectation of harm to themother
if the pregnancy was continued.
Implications for research
Large trials are needed to confirm whether the benefits for the
child associated with a policy of expectant care are real, and to
provide reassurance that there is no increase in risk of morbidity
or mortality for the mother.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
GRIT 2003
Methods Multi-centre randomised controlled trial.
Setting: 69 hospitals in 13 European countries.
Participants 547women (588 babies) recruited, outcomeswere available on 547mothers (587 babies)
Inclusion criteria: pregnant women with fetal compromise between 24 and 36 weeks, an
umbilical arteryDoppler waveform recorded and clinical uncertainty whether immediate
delivery was indicated
Interventions Immediate delivery (n = 273) (IPD n = 141): deliver now, within 48 hrs to permit
completion of a steroid course
Delayed delivery (n = 274) (IPD n = 121): defer delivery, meaning until delivery could
safely be delayed no longer
Outcomes Infant survival to hospital discharge and the Griffith’s development quotient at 2 years
of age
The trial was for compromised preterm fetus: a subset of women within this trial had
severe PE. IPD were available for this subset and these are the data which have been
extracted and analysed for this review. The outcomes for this subset were as follows
For the woman: CS.
For the baby:
intraventricular haemorrhage and/or hypoxic ischaemic encephalopathy;
Apgar score at 5 minutes;
neonatal seizures;
necrotising enterocolitis;
ventilation;
measures of long-term growth and development (e.g. CP diagnosis, Griffiths score);
gestational age at birth.
Notes Only a subset of IPD data were included and analysed in this review (women with
hypertension plus either proteinuria or IUGR)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A paper based number sequence with bal-
anced blocks of 8-12 weeks used except
during office hours when a computer-gen-
erated sequence was used.”
Allocation concealment (selection bias) Low risk “An independent programmer organised
allocation, using both randomisation and
minimisation.” “The process was designed
to mask allocation from participating clin-
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GRIT 2003 (Continued)
icians, including those with access to the
central trial office.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Not possible to blind - but most of the out-
comes not likely to be influenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Some blinding of outcome assessment for
long-term outcomes such as Griffiths as-
sessment: “Assessors were masked to the
child’s group allocations”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk A subset of IPD data was provided of
women with severe PE (n = 262 - hyperten-
sion and IUGR and/or proteinuria). It is
not possible to tell how complete this data
set is, as it was provided by the authors of
the original study
Selective reporting (reporting bias) Low risk All expected outcomes appear to have been
reported upon.
Other bias Unclear risk Unclear. Other bias may have been intro-
duced as only a subset of the original ran-
domised sample has provided data for anal-
ysis
Mesbah 2003
Methods Randomisation was generated from a random number sequence table. Blind allocation
was made using consecutively sealed envelopes. Odd numbers = aggressive management,
even numbers = expectant management. Analysis was by ITT. Follow-up was judged to
be 100%
Participants 30 pregnant women with severe PE between 28 and 33 + 6 days gestation. Severe PE was
defined as a BP > 180/120 mmHg on 2 occasions 30 minutes apart; or a BP between
160 to 180/110 to 120 mmHg on 2 occasions 6 hrs apart. All participants had > 500 mg
of proteinuria on a 24 hr urine collection measure. Exclusions were women who needed
delivery for either a maternal or fetal condition in the 1st 24 hrs
Interventions The group assigned to aggressive management were given steroids and then allowed
48 hrs to lapse before either an induction of labour was attempted or CS carried out.
Women assigned to expectant management also had steroids but were then managed
conservatively with bed rest, observations and nifedipine to control their BP. The indi-
cations for delivery in expectant management were, imminent eclampsia, deteriorating
renal function, spontaneous preterm labour, absent EDF or a non-reassuring CTG, and
reaching 34 weeks
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Mesbah 2003 (Continued)
Outcomes Women: days of hospitalisation, imminent eclampsia, eclampsia, HELLP, CS, imminent
eclampsia and deteriorating renal function
Baby: days gained in utero, gestation at delivery, birthweight, admission to SCBU, SGA,
stillbirth, neonatal death, 5-minute Apgar score
Notes Although in table 2 the total number in the expectant arm is recorded as 10 participants,
however, the detail of the table and percentages use the denominator 15. The total looks
as if it is a typographical error. Information is being sought from the author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random sequence generated by going
through random number tables till we ob-
tained 30 pairs of numbers from 01 to 30.
”
Allocation concealment (selection bias) Low risk “Randomly assigned to one of twomanage-
ment groups by withdrawing the next en-
velope in a series of 30 consecutively num-
bered, sealed, opaque envelopes.”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No blinding reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No blinding reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 41 women were recruited - but 11 (27%)
judged too compromised for expectant
management and were delivered by CS
5 patients from the expectant group appear
to be missing from results table 2 - no ex-
planation
Selective reporting (reporting bias) Low risk All expected outcomes appear to be re-
ported.
Other bias High risk Severe group were excluded from the study
andnobaseline characteristics described for
this group of patients. 5 patients missing
from results for expectant group and no ex-
planation given in the text
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Odendaal 1990
Methods Described as ’randomised’. No further information. Blinding in the assessment of out-
come not mentioned. Analysis - ITT basis. Follow-up - 100%
Participants 38 women with severe PE at 28-34 weeks’ gestation. Severe PE defined in 4 ways,
depending on BP, proteinuria and symptoms. Women were either already admitted
for bed rest and later met criteria, or admitted because of severe PE and after 48 hrs
stabilisation met entry criteria. 10 primigravidae per group.
Exclusions: oral antihypertensives before trial entry. Fetal or maternal complications
within 48 hrs (20 women excluded before randomisation for this reason)
Interventions All eligible women in 48 hrs before trial entry:MgSO4 for 24 hrs. If BP 160/110 mmHg,
or more, 6.25 mg dihydralazine boluses. If steroids not already given, betamethasone 12
mg IM and again after 24 hrs
Interventionist: delivery by either CS or by induction of labour, depending on obstetric
circumstances. If cervix not favourable, prostaglandin E2 tablets. If still not favourable
after 24 hrs, CS.
Expectant: bed rest on high-risk obstetric ward, BP controlled with prazosin, weekly be-
tamethasone. Maternal and fetal condition monitored intensively. Delivery as 34 weeks,
unless indicated earlier
Outcomes Women: CS, abruption.
Baby: stillbirth, neonatal death,HMD,NEC, pneumothorax, ventilation, days inNICU
(mean), birthweight (mean), gestation at delivery (mean)
Notes 8 women in the interventionist group and 5 in the expectant group deteriorated while
in hospital on bed rest and were randomised immediately.
The trial recruited from January 1986 to January 1988.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 58 women eligible with severe PE; 20 had
to be delivered before randomisation be-
cause of severe maternal complications or
fetal distress.
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Odendaal 1990 (Continued)
20 were randomised to the aggressive-man-
agement group; 18 were randomised to the
expectant group - not clear from results ta-
bles how many analysed - but presume no
loss to follow-up as not described in the text
ITT not stated.
Selective reporting (reporting bias) Low risk All expected outcomes reported
upon.
Other bias Low risk Groups seem similar - including 20 women
excluded prior to randomisation (corre-
spondence with author)
Sibai 1994
Methods Randomisation was by computer-generated random number. Concealment of allocation
by consecutively-numbered sealed, opaque, envelopes. Analysis - ITT basis. Follow-up
- 100%
Participants 95 women with severe PE at 28-32 weeks’ gestation. Severe PE defined as a persistent
elevation of BP >/= 160/110 mmHg, proteinuria > 500 mg in 24 hrs and uric acid > 5
mg/dL.
Exclusions: associated medical conditions, renal failure, diabetes or connective tissue
disorders, associated obstetric complications, multiple pregnancies and preterm labour
Interventions All eligible women in 24 hrs before trial entry: betamethasone 12 mg, repeated after
24 hrs, MgSO4 for 24 hrs. If BP 160/110 mmHg or more, hydralazine or nifedipine
depending on clinician preference
Interventionist: delivery by either CS or by induction of labour, on the basis of their
obstetric condition.
Expectant: maternal and fetal monitoring on an antenatal ward. If either the maternal
or fetal condition deteriorated or they reached 34 weeks’ gestation, delivery using the
most appropriate method
Outcomes Women: eclampsia, gestation at delivery (mean), CS, placental abruption, HELLP syn-
drome, renal failure, pulmonary oedema, postpartum length of stay.
Baby: birthweight (mean), admission to NICU, length of stay in NICU, SGA, RDS,
NEC, bronchopulmonary dysplasia, cerebral haemorrhage
Notes The trial recruited from January 1991 to July 1993.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated random
assignments.”
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Sibai 1994 (Continued)
Allocation concealment (selection bias) Low risk “Consecutively numbered, sealed, opaque
envelopes.”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 129 women had severe PE, but 32 of these
were ineligible because they met 1 or more
of the exclusion criteria and 2 refused to
participate - 95 women were randomised
(expectant management n = 49; aggressive
management n = 46).
All women appear to have been ac-
counted for in the results. Appears to be
ITT.
Selective reporting (reporting bias) Low risk All expected outcomes appear to have been
reported upon.
Other bias Low risk The 2 groups were similar with respect to
clinical and laboratory findings
BP: blood pressure
CP: cerebral palsy
CS: caesarean section
CTG: cardiotocography
EDF: end diastolic flow
HELLP: haemolysis elevated liver enzymes and lowered platelets
HMD: hyaline membrane disease
hrs: hours
IM: intramuscular
IPD: individual patient data
ITT: intention-to-treat
IUGR: intrauterine growth restriction
MgSO4: magnesium sulphate
NEC: necrotising enterocolitis
NICU: neonatal intensive care unit
PE: pre-eclampsia
RDS: respiratory distress syndrome
SCBU: special care baby unit
SGA: small-for-gestational age
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Gruppo di Studio1998 Not women with severe pre-eclampsia.
This randomised trial compared routine treatment with calcium channel blockers in mild to moderate
hypertension
Langenveld 2011 Not women with severe pre-eclampsia.
Thismulti-centre, randomised trial compared induction of labour versus expectant monitoring for gestation
hypertension or mild pre-eclampsia
Characteristics of ongoing studies [ordered by study ID]
Duvekot 2011
Trial name or title TOTEM study (temporise or terminate pregnancy in women with severe pre-eclampsia at 28-34 weeks): a
study protocol
Methods Randomised controlled trial.
Multi-centre trial - women admitted in all Dutch tertiary care hospitals
Participants Women with severe pre-eclampsia, gestational age at inclusion of 27.6 to 33.5 weeks, singleton pregnancy,
estimated fetal weight 500 g and no known major fetal congenital abnormalities
Interventions Delivery at least 48 hours after admission (described as “termination of pregnancy”) OR expectant manage-
ment
Outcomes Primary outcomes: composite major maternal and neonatal morbidity and mortality
Short-term maternal outcome is defined as the occurrence of major complications (pulmonary oedema,
encephalopathy/eclampsia, acute respiratory distress syndrome, cerebrovascular incident, abruption placentae,
liver haematoma/liver rupture, acute fatty liver of pregnancy, severe renal insufficiency, thromboembolism)
Secondary outcomes: long-term neonatal outcome using Bailey-3 assessment and maternal long-term out-
come defined as persistent morbidity
Starting date Randomisation during 60 months. Start randomisation June 2011
Contact information Duvekot JJ et al on behalf of the TOTEM study collaboration group Erasmus MC, Rotterdam, The Nether-
lands
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Eclampsia 1 95 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 HELLP syndrome 1 95 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.05, 5.68]
3 Pulmonary oedema 1 95 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Death of the baby (all stillbirths,
neonatal and infant deaths)
4 425 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.69, 1.71]
5 Death of the baby (subgrouped
by time of death)
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Stillbirth 4 425 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.03, 1.16]
5.2 Perinatal death 2 68 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.45, 2.89]
5.3 Neonatal death 4 425 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.80, 2.23]
5.4 Death after 28 days 1 38 Risk Ratio (M-H, Fixed, 95% CI) 1.8 [0.18, 18.21]
6 Intraventricular haemorrhage
or hypoxic ischaemic
encephalopathy
1 262 Risk Ratio (M-H, Fixed, 95% CI) 1.82 [1.06, 3.14]
7 Renal failure 2 133 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.01, 6.97]
8 Caesarean section 4 425 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [1.01, 1.18]
9 Placental abruption 2 133 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.26, 2.40]
10 Low Apgar score at five minutes
(< 7 at five minutes)
1 262 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.87, 2.50]
11 Neonatal seizures 1 262 Risk Ratio (M-H, Fixed, 95% CI) 2.57 [0.27, 24.43]
12 Hyaline membrane disease 2 133 Risk Ratio (M-H, Fixed, 95% CI) 2.30 [1.39, 3.81]
13 Necrotising enterocolitis 3 395 Risk Ratio (M-H, Fixed, 95% CI) 2.10 [0.93, 4.79]
14 Baby ventilated 2 300 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [1.11, 2.02]
15 Measures of long-term growth
& development (cerebral palsy)
1 262 Risk Ratio (M-H, Fixed, 95% CI) 6.01 [0.75, 48.14]
16 Measures of long-term
growth & development (poor
hearing/hearing aid)
1 262 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.07, 1.74]
17 Measures of long-term growth
& development (impaired
vision)
1 262 Risk Ratio (M-H, Fixed, 95% CI) 4.29 [0.51, 36.22]
18 Small-for-gestational age 2 125 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.14, 0.65]
19 Gestation at birth (days) 4 425 Mean Difference (IV, Random, 95% CI) -9.91 [-16.37, -3.45]
20 Length of stay in neonatal
intensive care unit (days)
2 125 Mean Difference (IV, Random, 95% CI) 11.14 [1.57, 20.72]
21 Admission to neonatal intensive
care unit
2 125 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [1.16, 1.58]
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Analysis 1.1. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 1 Eclampsia.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 1 Eclampsia
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sibai 1994 0/46 0/49 Not estimable
Total (95% CI) 46 49 Not estimable
Total events: 0 (Interventionist), 0 (Expectant)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours intervention Favours expectant
Analysis 1.2. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 2 HELLP syndrome.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 2 HELLP syndrome
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sibai 1994 1/46 2/49 100.0 % 0.53 [ 0.05, 5.68 ]
Total (95% CI) 46 49 100.0 % 0.53 [ 0.05, 5.68 ]
Total events: 1 (Interventionist), 2 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours intervention Favours expectant
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Analysis 1.3. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 3 Pulmonary oedema.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 3 Pulmonary oedema
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sibai 1994 0/46 0/49 Not estimable
Total (95% CI) 46 49 Not estimable
Total events: 0 (Interventionist), 0 (Expectant)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours intervention Favours expectant
Analysis 1.4. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 4 Death of the baby (all stillbirths, neonatal and infant deaths).
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 4 Death of the baby (all stillbirths, neonatal and infant deaths)
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sibai 1994 0/46 0/49 Not estimable
Odendaal 1990 5/20 3/18 11.0 % 1.50 [ 0.42, 5.41 ]
Mesbah 2003 6/15 4/15 13.9 % 1.50 [ 0.53, 4.26 ]
GRIT 2003 22/141 20/121 75.0 % 0.94 [ 0.54, 1.64 ]
Total (95% CI) 222 203 100.0 % 1.08 [ 0.69, 1.71 ]
Total events: 33 (Interventionist), 27 (Expectant)
Heterogeneity: Chi2 = 0.86, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours intervention Favours expectant
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Analysis 1.5. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 5 Death of the baby (subgrouped by time of death).
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 5 Death of the baby (subgrouped by time of death)
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Stillbirth
Sibai 1994 0/46 0/49 Not estimable
Mesbah 2003 0/15 0/15 Not estimable
Odendaal 1990 0/20 1/18 22.6 % 0.30 [ 0.01, 6.97 ]
GRIT 2003 1/141 5/121 77.4 % 0.17 [ 0.02, 1.45 ]
Subtotal (95% CI) 222 203 100.0 % 0.20 [ 0.03, 1.16 ]
Total events: 1 (Interventionist), 6 (Expectant)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.79 (P = 0.073)
2 Perinatal death
Odendaal 1990 1/20 2/18 34.5 % 0.45 [ 0.04, 4.55 ]
Mesbah 2003 6/15 4/15 65.5 % 1.50 [ 0.53, 4.26 ]
Subtotal (95% CI) 35 33 100.0 % 1.14 [ 0.45, 2.89 ]
Total events: 7 (Interventionist), 6 (Expectant)
Heterogeneity: Chi2 = 0.89, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
3 Neonatal death
Sibai 1994 0/46 0/49 Not estimable
Odendaal 1990 3/20 1/18 5.0 % 2.70 [ 0.31, 23.69 ]
Mesbah 2003 6/15 4/15 18.9 % 1.50 [ 0.53, 4.26 ]
GRIT 2003 21/141 15/121 76.2 % 1.20 [ 0.65, 2.23 ]
Subtotal (95% CI) 222 203 100.0 % 1.33 [ 0.80, 2.23 ]
Total events: 30 (Interventionist), 20 (Expectant)
Heterogeneity: Chi2 = 0.56, df = 2 (P = 0.75); I2 =0.0%
0.01 0.1 1 10 100
Favours intervention Favours expectant
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(. . . Continued)
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 1.09 (P = 0.28)
4 Death after 28 days
Odendaal 1990 2/20 1/18 100.0 % 1.80 [ 0.18, 18.21 ]
Subtotal (95% CI) 20 18 100.0 % 1.80 [ 0.18, 18.21 ]
Total events: 2 (Interventionist), 1 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
0.01 0.1 1 10 100
Favours intervention Favours expectant
Analysis 1.6. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 6 Intraventricular haemorrhage or hypoxic ischaemic encephalopathy.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 6 Intraventricular haemorrhage or hypoxic ischaemic encephalopathy
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
GRIT 2003 34/141 16/121 100.0 % 1.82 [ 1.06, 3.14 ]
Total (95% CI) 141 121 100.0 % 1.82 [ 1.06, 3.14 ]
Total events: 34 (Interventionist), 16 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 2.17 (P = 0.030)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours intervention Favours expectant
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Analysis 1.7. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 7 Renal failure.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 7 Renal failure
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Odendaal 1990 0/20 1/18 100.0 % 0.30 [ 0.01, 6.97 ]
Sibai 1994 0/46 0/49 Not estimable
Total (95% CI) 66 67 100.0 % 0.30 [ 0.01, 6.97 ]
Total events: 0 (Interventionist), 1 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours intervention Favours expectant
Analysis 1.8. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 8 Caesarean section.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 8 Caesarean section
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mesbah 2003 11/15 9/15 5.1 % 1.22 [ 0.73, 2.04 ]
Odendaal 1990 14/20 15/18 9.0 % 0.84 [ 0.59, 1.20 ]
Sibai 1994 39/46 36/49 19.9 % 1.15 [ 0.94, 1.42 ]
GRIT 2003 137/141 107/121 65.9 % 1.10 [ 1.02, 1.18 ]
Total (95% CI) 222 203 100.0 % 1.09 [ 1.01, 1.18 ]
Total events: 201 (Interventionist), 167 (Expectant)
Heterogeneity: Chi2 = 2.60, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.33 (P = 0.020)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours intervention Favours expectant
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Analysis 1.9. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 9 Placental abruption.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 9 Placental abruption
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sibai 1994 2/46 2/49 31.5 % 1.07 [ 0.16, 7.25 ]
Odendaal 1990 3/20 4/18 68.5 % 0.68 [ 0.17, 2.62 ]
Total (95% CI) 66 67 100.0 % 0.80 [ 0.26, 2.40 ]
Total events: 5 (Interventionist), 6 (Expectant)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 10 Low Apgar score at five minutes (< 7 at five minutes).
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 10 Low Apgar score at five minutes (< 7 at five minutes)
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
GRIT 2003 31/141 18/121 100.0 % 1.48 [ 0.87, 2.50 ]
Total (95% CI) 141 121 100.0 % 1.48 [ 0.87, 2.50 ]
Total events: 31 (Interventionist), 18 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 11 Neonatal seizures.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 11 Neonatal seizures
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
GRIT 2003 3/141 1/121 100.0 % 2.57 [ 0.27, 24.43 ]
Total (95% CI) 141 121 100.0 % 2.57 [ 0.27, 24.43 ]
Total events: 3 (Interventionist), 1 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 12 Hyaline membrane disease.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 12 Hyaline membrane disease
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Odendaal 1990 11/20 4/18 28.3 % 2.48 [ 0.96, 6.41 ]
Sibai 1994 23/46 11/49 71.7 % 2.23 [ 1.23, 4.04 ]
Total (95% CI) 66 67 100.0 % 2.30 [ 1.39, 3.81 ]
Total events: 34 (Interventionist), 15 (Expectant)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 3.23 (P = 0.0012)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 13 Necrotising enterocolitis.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 13 Necrotising enterocolitis
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sibai 1994 5/46 0/49 6.1 % 11.70 [ 0.67, 205.88 ]
Odendaal 1990 3/20 1/18 13.2 % 2.70 [ 0.31, 23.69 ]
GRIT 2003 9/141 6/121 80.8 % 1.29 [ 0.47, 3.51 ]
Total (95% CI) 207 188 100.0 % 2.10 [ 0.93, 4.79 ]
Total events: 17 (Interventionist), 7 (Expectant)
Heterogeneity: Chi2 = 2.35, df = 2 (P = 0.31); I2 =15%
Test for overall effect: Z = 1.77 (P = 0.076)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 14 Baby ventilated.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 14 Baby ventilated
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Odendaal 1990 7/20 2/18 4.7 % 3.15 [ 0.75, 13.25 ]
GRIT 2003 66/141 40/121 95.3 % 1.42 [ 1.04, 1.93 ]
Total (95% CI) 161 139 100.0 % 1.50 [ 1.11, 2.02 ]
Total events: 73 (Interventionist), 42 (Expectant)
Heterogeneity: Chi2 = 1.15, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 2.62 (P = 0.0089)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 15 Measures of long-term growth & development (cerebral palsy).
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 15 Measures of long-term growth % development (cerebral palsy)
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
GRIT 2003 7/141 1/121 100.0 % 6.01 [ 0.75, 48.14 ]
Total (95% CI) 141 121 100.0 % 6.01 [ 0.75, 48.14 ]
Total events: 7 (Interventionist), 1 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 16 Measures of long-term growth & development (poor hearing/hearing aid).
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 16 Measures of long-term growth % development (poor hearing/hearing aid)
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
GRIT 2003 2/141 5/121 100.0 % 0.34 [ 0.07, 1.74 ]
Total (95% CI) 141 121 100.0 % 0.34 [ 0.07, 1.74 ]
Total events: 2 (Interventionist), 5 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 17 Measures of long-term growth & development (impaired vision).
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 17 Measures of long-term growth % development (impaired vision)
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
GRIT 2003 5/141 1/121 100.0 % 4.29 [ 0.51, 36.22 ]
Total (95% CI) 141 121 100.0 % 4.29 [ 0.51, 36.22 ]
Total events: 5 (Interventionist), 1 (Expectant)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 18 Small-for-gestational age.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 18 Small-for-gestational age
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mesbah 2003 2/15 9/15 38.3 % 0.22 [ 0.06, 0.86 ]
Sibai 1994 5/46 15/49 61.7 % 0.36 [ 0.14, 0.90 ]
Total (95% CI) 61 64 100.0 % 0.30 [ 0.14, 0.65 ]
Total events: 7 (Interventionist), 24 (Expectant)
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 19 Gestation at birth (days).
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 19 Gestation at birth (days)
Study or subgroup Interventionist Expectant
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Odendaal 1990 20 211 (15) 18 223 (13) 20.7 % -12.00 [ -20.90, -3.10 ]
Mesbah 2003 15 213 (12) 15 217 (11) 22.0 % -4.00 [ -12.24, 4.24 ]
Sibai 1994 46 216 (14) 49 233 (11) 28.2 % -17.00 [ -22.08, -11.92 ]
GRIT 2003 141 217 (17) 121 223 (21) 29.0 % -6.00 [ -10.68, -1.32 ]
Total (95% CI) 222 203 100.0 % -9.91 [ -16.37, -3.45 ]
Heterogeneity: Tau2 = 31.74; Chi2 = 12.30, df = 3 (P = 0.01); I2 =76%
Test for overall effect: Z = 3.01 (P = 0.0026)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 20 Length of stay in neonatal intensive care unit (days).
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 20 Length of stay in neonatal intensive care unit (days)
Study or subgroup Interventionist Expectant
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Sibai 1994 46 36.6 (17.4) 49 20.2 (14) 46.4 % 16.40 [ 10.02, 22.78 ]
Mesbah 2003 15 22.3 (5.8) 15 15.7 (4.5) 53.6 % 6.60 [ 2.89, 10.31 ]
Total (95% CI) 61 64 100.0 % 11.14 [ 1.57, 20.72 ]
Heterogeneity: Tau2 = 40.93; Chi2 = 6.78, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 2.28 (P = 0.023)
Test for subgroup differences: Not applicable
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Analysis 1.21. Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 21 Admission to neonatal intensive care unit.
Review: Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation
Comparison: 1 Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome: 21 Admission to neonatal intensive care unit
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mesbah 2003 15/15 10/15 22.4 % 1.48 [ 1.02, 2.13 ]
Sibai 1994 46/46 37/49 77.6 % 1.32 [ 1.12, 1.55 ]
Total (95% CI) 61 64 100.0 % 1.35 [ 1.16, 1.58 ]
Total events: 61 (Interventionist), 47 (Expectant)
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.93 (P = 0.000084)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Search strategy
CENTRAL (The Cochrane LIbrary 2006, Issue 2)
#1 MeSH descriptor Pregnancy explode all trees in MeSH products
#2 MeSH descriptor Pregnancy Complications explode all trees in MeSH products
#3 preeclamp* in All Fields in all products
#4 pre-eclamp* in All Fields in all products
#5 pre next eclamp* in All Fields in all products
#6 eclamp* in All Fields in all products
#7 hypertens* in All Fields in all products
#8 #1 or #2
#9 #3 or #4 or #5 or #6 or #7
#10 aggressive near management in All Fields in all products
#11 early near delivery in All Fields in all products
#12 expectant near management in All Fields in all products
#13 delayed near delivery in All Fields in all products
#14 #10 or #11 or #12 or #13
#15 #8 and #9 and #14
Appendix 2. Methods used to assess trials included in previous versions of this review
The following methods were used to assess Odendaal 1990 and Sibai 1994.
Two review authors assessed potentially eligible trials for their suitability for inclusion in the review. Decisions regarding inclusion were
made separately and results compared. Any disagreement was resolved through discussion. Data were extracted by two authors using
an agreed format, and again discrepancies resolved through discussion. If agreement could not be reached that item was excluded until
further information was available from the trialists. Data were entered by one author, and double checked by the other.
Validity of each included trial was assessed according to the criteria outlined in the Cochrane Reviewers’ Handbook (Higgins 2005).
Trials were assessed with a grade allocated to each trial on the basis of allocation concealment: A (adequate), B (unclear), or C (clearly
inadequate). Where the method of allocation concealment was unclear, attempts were made to contact authors to provide further
details. Quasi-randomised designs, such as alternate allocation and use of record numbers, were excluded.
Blinding and completeness of follow-up were assessed for each outcome using the following criteria:
For completeness of follow-up:
A. less than 3% of participants excluded;
B. 3% to 9.9% of participants excluded;
C. 10% to 19.9% of participants excluded.
Excluded: if not possible to present the data by intention to treat or if more than 20% of participants were excluded.
For blinding of assessment of outcome:
A. double blind;
B. single blind;
C. no blinding or blinding not mentioned.
Excluded: no blinding and the outcome very subjective.
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Statistical analyses were carried out using the Review Manager software (RevMan 2000) with results presented as summary relative
risk, risk difference and number needed to treat. Tests of heterogeneity between trials were applied to assess the significance of any
differences between trials and possible causes of any heterogeneity were explored.
Wherever possible, subgroup analyses for the main outcomes were performed by gestation at trial entry (24 to 28 weeks and 29 to 34
weeks), severity of pre-eclampsia (HELLP syndrome or imminent eclampsia and neither of these).
WH A T ’ S N E W
Last assessed as up-to-date: 10 July 2013.
Date Event Description
10 July 2013 New citation required and conclusions have changed Expectant management may be associated with de-
creased morbidity for the baby
28 February 2013 New search has been performed Search updated. Methods updated.
Three studies identified from updated search (Duvekot
2011; GRIT 2003; Langenveld 2011). One study has
been included (GRIT 2003); one is an ongoing study
(Duvekot 2011); and one study has been excluded (
Langenveld 2011).
One study previously in studies awaiting assessment in
the last update has now been included (Mesbah 2003).
H I S T O R Y
Protocol first published: Issue 2, 2001
Review first published: Issue 3, 2002
Date Event Description
16 February 2010 New search has been performed Review updated with new report added to Characteristics of studies awaiting
classification
1 December 2009 Amended Search updated. One new report added to Studies awaiting classification
(Mesbah 2003a)
15 May 2008 Amended Converted to new review format.
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C O N T R I B U T I O N S O F A U T H O R S
Lelia Duley and David Churchill contributed to the development of the protocol. Both authors assessed potentially eligible studies for
inclusion in the first version of this review, and extracted data. D Churchill entered data, and these were checked by L Duley. Both
authors contributed to writing the review.
For the 2013 update, Leanne Jones updated the methods and assessed studies for inclusion, extracted data, entered data, and these were
checked by David Churchill. Leanne Jones wrote the first draft of the updated results. David Churchill, Lelia Duley and Jim Thornton
commented on all drafts of the 2013 update and made edits.
D E C L A R A T I O N S O F I N T E R E S T
Jim Thornton is an author on one of the included studies (GRIT 2003). However, he was not involved in any assessment, data extraction
or data analysis of this trial.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
UK NIHR Programme of centrally-managed pregnancy and childbirth systematic reviews of priority to the NHS and users of the
NHS: 10/4001/02
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In 2013, the methods were updated. The inclusion criteria were modified to define more clearly the criteria for types of participants:
Women with severe pre-eclampsia before or equal to 34 weeks’ gestation. Severe pre-eclampsia was defined as high blood pressure, >
140/90 mmHg on two consecutive occasions four or more hours apart and proteinuria greater than 300 mg/24 hours. Alternatively as:
• severe hypertension (blood pressure at least 160 mmHg systolic, or 110 mmHg diastolic) alone;
or hypertension as defined above plus one or more of the following criteria:
• severe proteinuria (usually at least 3 g (range 2 g to 5 g) protein in 24 hours, or 3+ on dipstick);
• reduced urinary volume (less than 500 mL in 24 hours), upper abdominal pain, pulmonary oedema;
• neurological disturbances (such as headache, visual disturbances, and exaggerated tendon reflexes);
• impaired liver function tests, high serum creatinine, low platelets;
• suspected intrauterine growth restriction or reduced liquor volume.
This latter set of criteria reflect the natural history of the disease and clinical practice when diagnosing severe pre-eclampsia.
Primary and secondary outcomes were defined.
40Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Delivery, Obstetric [adverse effects; methods]; ∗Watchful Waiting; Cesarean Section [statistics & numerical data]; Enterocolitis,
Necrotizing [etiology]; Hyaline Membrane Disease [etiology]; Pre-Eclampsia [∗therapy]; Randomized Controlled Trials as Topic
MeSH check words
Female; Humans; Infant, Newborn; Pregnancy
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